THE EFFECT OF MONOSIALOGANGLYOSIDE (GM-1) ADMINISTRATION IN SPINAL CORD INJURY
Carregando...
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2016
Título da Revista
ISSN da Revista
Título do Volume
Editora
ATHA COMUNICACAO & EDITORA
Citação
ACTA ORTOPEDICA BRASILEIRA, v.24, n.3, p.123-126, 2016
Resumo
Objective: To evaluate the effect of monosialoganglioside (GM-1) in spinal cord trauma patients seen in our service who have not been treated with methylprednisolone. Methods: Thirty patients with acute spinal cord trauma were randomly divided into two groups. In Group 1, patients received 200 mg GM-1 in the initial assessment and thereafter received 100 mg intravenous per day for 30 days and Group 2 (control) received saline. Patients were evaluated periodically (at 6 weeks, 6 months, one year and two years), using a standardized neurological assessment of the American Spinal Injury Association / International Spinal Cord Society. Results: The comparative statistical analysis of motor indices, sensitive indices for pain and touch according to the standardization of ASIA / ISCOS showed that the assessments at 6 weeks, 6 months and 2 years, GM-Group 1 patients had higher rates than the control group regarding sensitivity to pain and touch, with no statistically significant difference from the motor index. Conclusion: The functional assessment showed improvement in the sensitive indices of patients treated with GM1 after post-traumatic spinal cord injury compared to patients who received placebo.
Palavras-chave
Spinal cord injuries, G(M1) Ganglioside, Outcome assessment (Health care)
Referências
- Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699
- Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001
- Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002
- Banerjea R, 2008, ARCH PHYS MED REHAB, V89, P1448, DOI 10.1016/j.apmr.2007.12.047
- Ray SK, 2001, ANN NY ACAD SCI, V939, P436
- Short D, 2001, CURR OPIN NEUROL, V14, P759, DOI 10.1097/00019052-200112000-00013
- Fouad K, 2011, BRAIN RES BULL, V84, P337, DOI 10.1016/j.brainresbull.2010.04.017
- Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597
- Noonan VK, 2008, ARCH PHYS MED REHAB, V89, P1074, DOI 10.1016/j.apmr.2007.10.041
- Marcon RM, 2010, SPINAL CORD, V48, P808, DOI 10.1038/sc.2010.37
- BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023
- Cristante AF, 2012, CLINICS, V67, P1219, DOI 10.6061/clinics/2012(10)16
- Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915
- Krause JS, 2008, ARCH PHYS MED REHAB, V89, P1482, DOI 10.1016/j.apmr.2007.11.062
- Blight A R, 2001, Curr Opin Investig Drugs, V2, P801
- Gebrin AS, 1997, ACTA ORTOP BRAS, V5, P123
- Gebrin AS, 1997, REV BRAS ORTOP, V32, P103
- Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015
- Haan N., 2014, ADV WOUND CARE, V3, P156
- Marcon RM, 2014, EXPT STUDY FUNCTIONA
- Masini M., 2001, J BRAS NEUROCIRURG, V12, P97
- Ralchle KA, 2007, J PAIN, V8, P718, DOI 10.1016/j.jpain.2007.05.006
- Santos GB, 2010, FENS ANN, V5
- Souza FI, 2011, COLUNA COLUMNA, V10, P305
- Souza FI, 2013, ACTA ORTOP BRAS, V21, P87